Ensuring ACCESS TO SAFE AND EFFECTIVE MEDICINES FOR ALL is a complex challenge that requires innovation and collaboration.
Ensuring ACCESS TO SAFE AND EFFECTIVE MEDICINES FOR ALL is a complex challenge that requires innovation and collaboration.
Ensuring ACCESS TO SAFE AND EFFECTIVE MEDICINES FOR ALL is a complex challenge that requires innovation and collaboration.
MIT CBI is a COLLABORATION ENGINE that brings together the excellence of MIT researchers with stakeholders across the healthcare value chain.
MIT CBI is a COLLABORATION ENGINE that brings together the excellence of MIT researchers with stakeholders across the healthcare value chain.
MIT CBI is a COLLABORATION ENGINE that brings together the excellence of MIT researchers with stakeholders across the healthcare value chain.
Collaboratively, MIT CBI DESIGNS, TESTS, and IMPLEMENTS ways to ensure global access to safe and effective medicines.
Collaboratively, MIT CBI DESIGNS, TESTS, and IMPLEMENTS ways to ensure global access to safe and effective medicines.
Collaboratively, MIT CBI DESIGNS, TESTS, and IMPLEMENTS ways to ensure global access to safe and effective medicines.
CBI provides integrated solutions to global health
CBI Programs
Biomanufacturing@MIT-CBI focuses on technology, training, and knowledge networks in biomanufacturing to advance the safe, timely, and efficient production and delivery of biologic medicines.
MIT NEWDIGS is a global multi-stakeholder “think and do” tank focused on re-engineering drug therapy development, access, and use to be more patient-centered and economically sustainable.
Upcoming Events
Biomanufacturing@MIT-CBI
2021 Vaccines Bioprocess Development & Commercialization Short Course
Biomanufacturing@MIT-CBI Research Seminar Series 2021
NEWDIGS
FoCUS Design Lab
LEAPS Design Lab
Latest News & Research
Enroll in MIT xPro Course through March 3rd!
NEWDIGS offers comment on CMS Proposed Rule supporting Value-Based Purchasing, July 20th, 2020
Nature Biotechnology publishes CAACB Article on Viral Contamination in Biologic Manufacture and Implications for Emerging Therapies
Our Team
CBI’s core strength is in our team’s cross-cutting experience and expertise in medicine, biology, chemistry, biomanufacturing, academic & clinical research, economics, engineering, data analytics, regulatory science and public policy.
Our Members
Our members and collaborators are leading stakeholders across the global healthcare value chain, from R&D and manufacturing to delivery and reimbursement.
Slider shortcode: [smartslider3 slider="14"]